$398B is sitting in the European university spinout funnel. PhD founders are missing their share. Here’s why, and how to fix it.
Deep tech founders face a real paradox: the very complexity that makes their technology defensible is the same complexity that makes it nearly impossible to pitch.
Yet with a third of all global venture capital now flowing into deep tech, the stakes have never been higher. Founders who cannot translate their science into a clear commercial narrative are leaving serious money on the table, if they get funded at all. The disconnect isn’t just a lack of communication; it’s a demographic reality.
In Europe, only 52.5% of deep tech investors hold a STEM-related degree, and only 20% of funds have fully technical teams.
Why it Matters to Founders
The lesson for PhD founders is simple. Science alone doesn’t close rounds; commercial validation does. Investors are underwriting your team’s ability to hit “de-risking” milestones, and build a defensible solution. When you walk into a pitch meeting, there is a high probability that the person deciding on your Series A or Seed round cannot fully understand your IP. If you lack the fluency to translate that IP into a concrete outcome, you lose the room before you’ve even had a chance to flip through your slide deck.
Think about the most successful unicorns of the last few years. No matter where they are in the world, they didn’t just showcase better tech; they showcased better market traction.
Here are a few outside the US:
- Oxford OrganOx (UK): Scaled its perfusion technology to 6,000+ transplants before its $1.5B acquisition in 2025.
- Biomemory (France, Sorbonne): Secured an $18M Series A by proving DNA-based storage with zero energy requirements.
- Ookuma Diamond Device (Japan, Hokkaido U): Successfully commercialized diamond semiconductors for extreme environments like the Fukushima nuclear decommissioning site.
These weren’t just the best science; they were the best-translated science. OrganOx didn’t close a $1.5B acquisition because liver perfusion technology is self-evidently valuable. They closed it because they built a commercial narrative around 6,000 successful transplants that any investor could understand without a medical degree.
The best founders develop a dual fluency. They can geek out on science with a technical advisor, but they lead with the problem (and market solution) when speaking to a general partner.
- Don’t say: “Our platform processes genomic data 40x faster using proprietary algorithms.”
- Do say: “We reduce drug target identification from 18 months to 6 weeks, allowing pharma partners to reach clinical trials a full year early.”
One Action
Before your next pitch meeting, rewrite your two-minute opening from scratch — leading with the commercial outcome, not the technology. Test it on someone outside your field. If they can’t explain your value proposition back to you in one sentence, your translation isn’t working. Then check your lead partner’s LinkedIn. If they don’t hold a STEM degree, prepare a non-technical version of every technical claim in your deck before you walk in.
This isn’t just a pitch deck exercise. The European university spinout funnel alone is now worth $398 billion. In the UK, spinout investment bucked global downward trends with a 38% increase last year, and nearly 50% of that late-stage capital comes from US investors. Europe is not a consolation prize. The capital is global, the market is real, and it is moving. The only question is whether you can translate your breakthrough into something an investor — not just a scientist — can believe in.